2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.97 (Poster) Real-World Treatment Patterns Among Resected Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Atezolizumab

PP01.97 (Poster) Real-World Treatment Patterns Among Resected Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Atezolizumab

Back to course

Pdf Summary

This study analyzed real-world treatment patterns and duration of adjuvant atezolizumab in patients with non-small cell lung cancer (NSCLC). Most patients received adjuvant chemotherapy prior to atezolizumab treatment, with cisplatin or carboplatin-based regimens being the most common. The mean duration of adjuvant atezolizumab treatment was 54.2 weeks.<br /><br />The study found that the real-world duration of adjuvant chemotherapy and atezolizumab treatment was generally comparable to that observed in the IMpower010 clinical trial. At 48 weeks, 62% of patients were likely to continue atezolizumab treatment. <br /><br />The authors noted that further research with longer follow-up is needed to understand real-world clinical outcomes such as recurrence-free survival and overall survival. The study had limitations, including a small sample size and limited follow-up, and the results may not be generalizable to all patients with NSCLC.<br /><br />Overall, this study provides insights into real-world treatment patterns among NSCLC patients receiving adjuvant atezolizumab and highlights the need for further research in this area.

Asset Subtitle

Husam Albarmawi

Keywords

real-world treatment patterns

adjuvant atezolizumab

non-small cell lung cancer

NSCLC

adjuvant chemotherapy

cisplatin

carboplatin

duration of treatment

IMpower010 clinical trial

recurrence-free survival